Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma

G. Cesarman-Maus, Esteban D Braggio, H. Maldonado, Rafael Fonseca

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Thrombosis portends a poor prognosis in individuals with solid tumors. Constitutive expression of tissue factor (TF) by cancer cells is a key in triggering activation of coagulation and promoting aggressive tumor behavior. Though multiple myeloma (MM) is associated with a high frequency of thrombosis in the context of thalidomide and lenalidomide therapy, prognosis is not affected by its occurrence. We sought to determine the expression of TF in MM. F3 (TF gene) expression profiling was analyzed in 55 human MM cell lines (HMCL) and in 223 solid tumor cell lines obtained from GlaxoSmithKline (GSK) Cancer Cell Line Genomic Profiling Dataset. TF was not expressed in any of the 55 HMCLs studied, in sharp contrast to solid tumors, 90% of which showed TF expression. F3 expression was also absent in tumor samples from 239 MM patients. Immunohistochemistry for TF was negative, with either no or focal (1) staining in 70/73 MM patients. Only three marrow biopsies were moderately (2) positive either focally or diffusely, suggesting that in rare cases bone marrow microenvironment may support TF expression. General lack of TF expression by neoplastic plasma cells may explain why thrombosis is not predictive of poor outcome, and why aspirin prophylaxis is often effective in MM.

Original languageEnglish (US)
Pages (from-to)1671-1674
Number of pages4
JournalLeukemia
Volume26
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Thromboplastin
Plasma Cells
Multiple Myeloma
Neoplasms
Thrombosis
Bone Marrow
Cell Line
Thalidomide
Gene Expression Profiling
Tumor Cell Line
Aspirin
Immunohistochemistry
Staining and Labeling
Biopsy

Keywords

  • myeloma
  • thrombosis
  • tissue factor

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. / Cesarman-Maus, G.; Braggio, Esteban D; Maldonado, H.; Fonseca, Rafael.

In: Leukemia, Vol. 26, No. 7, 07.2012, p. 1671-1674.

Research output: Contribution to journalArticle

@article{eb73a4a249bb4e7baa001b8172d99d12,
title = "Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma",
abstract = "Thrombosis portends a poor prognosis in individuals with solid tumors. Constitutive expression of tissue factor (TF) by cancer cells is a key in triggering activation of coagulation and promoting aggressive tumor behavior. Though multiple myeloma (MM) is associated with a high frequency of thrombosis in the context of thalidomide and lenalidomide therapy, prognosis is not affected by its occurrence. We sought to determine the expression of TF in MM. F3 (TF gene) expression profiling was analyzed in 55 human MM cell lines (HMCL) and in 223 solid tumor cell lines obtained from GlaxoSmithKline (GSK) Cancer Cell Line Genomic Profiling Dataset. TF was not expressed in any of the 55 HMCLs studied, in sharp contrast to solid tumors, 90{\%} of which showed TF expression. F3 expression was also absent in tumor samples from 239 MM patients. Immunohistochemistry for TF was negative, with either no or focal (1) staining in 70/73 MM patients. Only three marrow biopsies were moderately (2) positive either focally or diffusely, suggesting that in rare cases bone marrow microenvironment may support TF expression. General lack of TF expression by neoplastic plasma cells may explain why thrombosis is not predictive of poor outcome, and why aspirin prophylaxis is often effective in MM.",
keywords = "myeloma, thrombosis, tissue factor",
author = "G. Cesarman-Maus and Braggio, {Esteban D} and H. Maldonado and Rafael Fonseca",
year = "2012",
month = "7",
doi = "10.1038/leu.2012.43",
language = "English (US)",
volume = "26",
pages = "1671--1674",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma

AU - Cesarman-Maus, G.

AU - Braggio, Esteban D

AU - Maldonado, H.

AU - Fonseca, Rafael

PY - 2012/7

Y1 - 2012/7

N2 - Thrombosis portends a poor prognosis in individuals with solid tumors. Constitutive expression of tissue factor (TF) by cancer cells is a key in triggering activation of coagulation and promoting aggressive tumor behavior. Though multiple myeloma (MM) is associated with a high frequency of thrombosis in the context of thalidomide and lenalidomide therapy, prognosis is not affected by its occurrence. We sought to determine the expression of TF in MM. F3 (TF gene) expression profiling was analyzed in 55 human MM cell lines (HMCL) and in 223 solid tumor cell lines obtained from GlaxoSmithKline (GSK) Cancer Cell Line Genomic Profiling Dataset. TF was not expressed in any of the 55 HMCLs studied, in sharp contrast to solid tumors, 90% of which showed TF expression. F3 expression was also absent in tumor samples from 239 MM patients. Immunohistochemistry for TF was negative, with either no or focal (1) staining in 70/73 MM patients. Only three marrow biopsies were moderately (2) positive either focally or diffusely, suggesting that in rare cases bone marrow microenvironment may support TF expression. General lack of TF expression by neoplastic plasma cells may explain why thrombosis is not predictive of poor outcome, and why aspirin prophylaxis is often effective in MM.

AB - Thrombosis portends a poor prognosis in individuals with solid tumors. Constitutive expression of tissue factor (TF) by cancer cells is a key in triggering activation of coagulation and promoting aggressive tumor behavior. Though multiple myeloma (MM) is associated with a high frequency of thrombosis in the context of thalidomide and lenalidomide therapy, prognosis is not affected by its occurrence. We sought to determine the expression of TF in MM. F3 (TF gene) expression profiling was analyzed in 55 human MM cell lines (HMCL) and in 223 solid tumor cell lines obtained from GlaxoSmithKline (GSK) Cancer Cell Line Genomic Profiling Dataset. TF was not expressed in any of the 55 HMCLs studied, in sharp contrast to solid tumors, 90% of which showed TF expression. F3 expression was also absent in tumor samples from 239 MM patients. Immunohistochemistry for TF was negative, with either no or focal (1) staining in 70/73 MM patients. Only three marrow biopsies were moderately (2) positive either focally or diffusely, suggesting that in rare cases bone marrow microenvironment may support TF expression. General lack of TF expression by neoplastic plasma cells may explain why thrombosis is not predictive of poor outcome, and why aspirin prophylaxis is often effective in MM.

KW - myeloma

KW - thrombosis

KW - tissue factor

UR - http://www.scopus.com/inward/record.url?scp=84863784755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863784755&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.43

DO - 10.1038/leu.2012.43

M3 - Article

C2 - 22333877

AN - SCOPUS:84863784755

VL - 26

SP - 1671

EP - 1674

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -